The judge blocked the emergency injunction motion on March 5, 2025. Find out exactly what this means for your pharmacy, prescribers, and patients.
Key Points:
- 503As must stop compounding any tirzepatide products on March 5, 2025.
- 503Bs must stop compounding any tirzepatide products on March 19, 2025.
- Very strong patents mean adding a vitamin or compounding into a different strength or dosage form and still using the API powder won't pass muster in most cases.
- Semaglutide dates haven't changed yet, and the motion for injuction is still being decided upon.
- There are other alternatives you can compound or dispense to continue to support your patients' health.
Watch the full replay here for all the details and tons of Q&A with Dr. Lisa Faast.
Pharmacy owners who want to increase profits are invited to join Pharmacy Badass University.